Journal Article

Successful management of severe diabetic ketoacidosis in a patient with type 2 diabetes with insulin allergy: a case report

Luong, Chinh Quoc, Mai, Ton Duy, Do, Son Ngoc, Nguyen, Nguyet Nhu, Nguyen, Dat Tuan, Dao, Phuong Viet, Nguyen, Anh Dat, Nguyen, Tuan Anh, Tran, Thong Huu, Nguyen, Dinh Van, Nguyen, Bay Quang, Nguyen, Van Khoa Dieu, Nguyen, Quan Huu, Chu, Hieu Chi, Nguyen, Chi Van

2019

Overview

Background Diabetic ketoacidosis (DKA) is an acute, major, life-threatening complication of diabetes that requires immediate treatment. Allergic reaction to insulin is rare, especially when using recombinant human insulin. The clinical presentation of insulin allergy can range from minor local symptoms to a severe generalized allergic reaction such as anaphylaxis. A limited number of cases have been reported on the treatment of severe DKA in patients with type 2 diabetes with insulin allergy. Here, we describe a patient with type 2 diabetes with insulin allergy in which severe DKA resolved after the initiation of continuous intravenous (IV) recombinant human insulin infusion. Case presentation A 58-year-old man with type 2 diabetes initiated subcutaneous insulin administration (SIA) after failure of oral antidiabetic treatment. Symptoms of an allergic reaction developed, including pruritic wheals appearing within 10 min of injection and lasting over 24 h. Both skin prick and intradermal tests were positive with different types of insulin. Two days before admission, he stopped SIA because of allergic symptoms and then experienced weakness and upper abdominal pain. On admission, he was in severe metabolic acidosis with a pH of 6.984 and bicarbonate of 2.5 mmol/litre. The blood glucose level was 20.79 mmol/litre, BUN 4.01 mmol/litre, creatinine 128 μmol/litre, and urinary ketone 11.44 mmol/litre. Over 24 h, metabolic acidosis was refractory to IV fluids, bicarbonate and potassium replacement, as well as haemodialysis. Ultimately, he received continuous IV recombinant human insulin infusion at a rate of 0.1 units/kg/hour, in combination with haemodiafiltration, and no further allergic reactions were observed. On day 5, ketonaemia and metabolic acidosis completely resolved. He had transitioned from IV insulin infusion to SIA on day 14. He was discharged on day 21 with SIA treatment. Three months later, he had good glycaemic control but still had allergic symptoms at the insulin injection sites. Conclusions In this patient, SIA caused an allergic reaction, in contrast to continuous IV insulin infusion for which allergic symptoms did not appear. Continuous IV recombinant human insulin infusion in combination with haemodiafiltration could be an option for the treatment of severe DKA in patients with diabetes with insulin allergy.

• Publisher: BioMed Central,BioMed Central Ltd,BMC
• Subject: Acidosis / Allergy / Anaphylaxis / Blood glucose / Carbonates / Care and treatment / Case Report / Continuous intravenous insulin infusion / Diabetes / Diabetes and Metabolism / Diabetes Mellitus, Type 2 - complications / Diabetes therapy / Diabetic ketoacidosis / Diabetic Ketoacidosis - drug therapy / Diabetic Ketoacidosis - etiology / Diabetics / Drug Hypersensitivity - etiology / Drug Hypersensitivity - prevention & control / Endocrinology / Glucose / Humans / Hypoglycemic agents / Infusions, Intravenous - methods / Insulin / Insulin - administration & dosage / Insulin - adverse effects / Insulin allergy / Insulin aspart / Insulin glargine / Insulin Infusion Systems / Insulin lispro / Male / Medical tests / Medicine / Medicine & Public Health / Metabolic Diseases / Middle Aged / Prognosis / Recombinant human insulin / rology / Sitagliptin / Skin / Type 2 diabetes